Editas Medicine (EDIT)

• Market cap: $99.9M
• 1 day: -0.82%
• 5 days: 4.31%
• 1 month: -3.20%
• 3 months: -67.82%
• 6 months: -76.78%
• Year to date: -7.63%
• 1 year: -85.47%
• 5 years: -95.96%
• 10 years: -93.35%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Employees: 226

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

32% more call options, than puts

Call options by funds: $1.5M | Put options by funds: $1.14M

2% less repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 65

10% less first-time investments, than exits

New positions opened: 37 | Existing positions closed: 41

3% less funds holding

Funds holding: 233 [Q2] → 227 (-6) [Q3]

2.87% less ownership

Funds ownership: 70.65% [Q2] → 67.79% (-2.87%) [Q3]

30% less capital invested

Capital invested by funds: $271M [Q2] → $190M (-$81M) [Q3]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 148% upside
• Avg. target: $5 313% upside
• High target: $8 561% upside

7 analyst ratings

• positive: 3 43%
• neutral: 4 57%
• negative: 0 0%

Evercore ISI Group Liisa Bayko 50% 1-year accuracy 6 / 12 met price target	313% upside $5	Outperform Maintained	16 Dec 2024
RBC Capital Luca Issi 17% 1-year accuracy 10 / 60 met price target	231% upside $4	Sector Perform Maintained	13 Dec 2024
Barclays Gena Wang 16% 1-year accuracy 5 / 31 met price target	148% upside $3	Equal-Weight Maintained	13 Dec 2024
Baird Joel Beatty 48% 1-year accuracy 20 / 42 met price target	561% upside $8	Outperform Maintained	13 Dec 2024
Stifel Dae Gon Ha 42% 1-year accuracy 5 / 12 met price target	148% upside $3	Hold Downgraded	13 Dec 2024